Cannabis withdrawal peaked at day 4 and THC lingered in blood for over two weeks | Research

The takeaway

Cannabis withdrawal symptoms peaked at day 4 of abstinence and declined by day 16, while nearly a third of patients still had detectable THC in their blood after 16 days of monitored abstinence.

Read this if you want to know what cannabis withdrawal actually looks like on a day-by-day timeline.

28% still had detectable blood THC after 16 days of confirmed abstinence

What the researchers found

Thirty-nine chronic cannabis-dependent patients were monitored during inpatient detoxification. Withdrawal symptoms peaked on day 4, with an average severity score of 10.4 out of 39 points, and declined to 2.9 points by day 16. The most dominant symptoms were craving, restlessness, nervousness, and sleeplessness. Clinical severity peaked at 5 out of 7 on a global impression scale ("markedly ill").

Women experienced significantly stronger withdrawal than men. On admission, THC and metabolite levels negatively correlated with withdrawal severity (higher levels meant less withdrawal, consistent with the pharmacological model). After admission, no correlation existed between blood levels and symptom severity.

Remarkably, 28.2% of patients still had THC blood levels above 1 ng/mL after 16 days of confirmed abstinence (range: 1.3 to 6.4 ng/mL), reflecting THC's storage in body fat and slow release.

Why it matters

This study provided a detailed clinical timeline of cannabis withdrawal under controlled conditions. The finding that THC persists in blood for over two weeks has implications for drug testing, driving assessments, and understanding why some withdrawal symptoms may be prolonged.

The numbers in context

39 patients. Withdrawal peaked day 4 (10.4/39 points), declined to 2.9/39 by day 16. CGI-S peaked at 5/7. 28.2% still had THC above 1 ng/mL at day 16. Women had significantly stronger withdrawal than men.

How the study worked

Prospective observational study of 39 treatment-seeking cannabis dependents (ICD-10) in inpatient detoxification. Assessments at admission and abstinence days 2, 4, 8, and 16 using the Marijuana Withdrawal Checklist (MWC) and Clinical Global Impression-Severity scale. Serum THC, THC-OH, and THC-COOH were measured simultaneously.

What this study cannot tell us

Relatively small sample of 39 patients. All were treatment-seeking, which may select for more severe dependence. Some patients received medications for withdrawal symptoms, though this did not affect the THC-withdrawal correlation. The study did not assess body composition, which affects THC storage and release.

How to read the evidence

Prospective inpatient study with objective blood measurements and validated withdrawal scales, though limited by small sample size.

When this study was published

Published in 2014.

The bigger picture

The disconnect between blood THC levels and withdrawal severity after the first day challenges simple pharmacological models of withdrawal. The slow clearance of THC from blood means that standard drug tests can remain positive for weeks after genuine abstinence, which has legal and employment implications.

Questions still open

Why do women experience stronger cannabis withdrawal? Does residual THC in blood contribute to prolonged or rebound symptoms? Would body fat percentage predict THC clearance rate and withdrawal timeline?

Common questions

When does cannabis withdrawal peak?

In this study, symptoms peaked at day 4 of abstinence, with craving, restlessness, nervousness, and sleeplessness as the dominant complaints. Symptoms declined substantially by day 16.

How long does THC stay in your blood after quitting?

After 16 days of confirmed inpatient abstinence, 28.2% of patients still had THC above 1 ng/mL in their blood (up to 6.4 ng/mL), reflecting THC stored in body fat being slowly released.

Read the original research

Abstinence phenomena of chronic cannabis-addicts prospectively monitored during controlled inpatient detoxification: cannabis withdrawal syndrome and its correlation with delta-9-tetrahydrocannabinol and -metabolites in serum.

Drug and alcohol dependence, 143, 189-97

View on PubMed ↗Publisher’s paper ↗

Citation

Bonnet, U; Specka, M; Stratmann, U; Ochwadt, R; Scherbaum, N. (2014). Abstinence phenomena of chronic cannabis-addicts prospectively monitored during controlled inpatient detoxification: cannabis withdrawal syndrome and its correlation with delta-9-tetrahydrocannabinol and -metabolites in serum.. Drug and alcohol dependence, 143, 189-97. https://doi.org/10.1016/j.drugalcdep.2014.07.027